Gwo Xi Stem Cell Applied Technology Co 6704.TWO · TWD
Health Care · Taipei Exchange · 🇹🇼 Taiwan
20.15
+0.75%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gwo Xi Stem Cell Applied Technology Co
Its shares trade on Taipei Exchange under the ticker 6704.TWO. It has been listed since 26 April 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 187.0m and a net loss of TWD 80.5m. At that date it held total assets of TWD 978.1m and shareholders' equity of TWD 580.4m.
Gwo Xi Stem Cell Applied Technology Co., Ltd. engages in the research and development of stem cell medicines/technologies for the treatment of intractable diseases. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2023-04-26. The firm owns the Medical-Grade Cell Preparation Platform for the collection, isolation, culture, scaling up, packaging, testing, transportation, storage and treatment of human stem cells. The platform is modularized to create the stem cell activation technology Nigiro-Med, medical grade stem cell storage service and clinical cell preparation quality testing service. The firm operates through Stem Cell Freezing segment, Health Care Products and Maintenance Products segment, and Other segment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Apr 2023
- Website
- gwoxi.com.tw ↗
Leadership
Pay as last reported
- Mr. Mingxi ZhuangChairman of the Board, since 2016
- Nuanxuan HeVice Chairman of the Board, since 2025
- Chunfen QiuGeneral Manager, Director
- Bairu ChenDirector
- Lixing HeDirector
- Xidong KangDirector
- Ling LuoDirector
- Yuting DaiIndependent Director
- Zhenyi WuIndependent Director
- Shidi YuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gwo Xi Stem Cell Applied Technology Co Ltd owns the Medical-Grade Cell Preparation Platform for stem cell treatment.
- The company's Nigiro-Med technology is modularized for stem cell activation and clinical use.
- Gwo Xi operates through three segments: Stem Cell Freezing, Health Care Products, and Maintenance Products.
Weaknesses
- The company's IPO was on 26 April 2023, a recent listing with limited market history.
- Gwo Xi is headquartered in Zhubei, Hsinchu, a city with limited global recognition.
- The firm's focus on stem cell technologies may face regulatory challenges in Health Care.
Opportunities
- The growing demand for stem cell treatments in Health Care presents a significant market opportunity.
- Gwo Xi's Medical-Grade Cell Preparation Platform can expand into new regions like Europe and North America.
- The company can leverage its Nigiro-Med technology for new clinical applications in intractable diseases.
Threats
- Regulatory changes in the Health Care sector could impact stem cell treatment approvals.
- Competition from established biotechnology firms in the Health Care industry is increasing.
- The company's recent IPO may lead to financial volatility in the stock market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.